Maternal anaemia is defined as:
- Haemoglobin concentration (Hb) <110g/l 1st trimester
- Hb <105g/l 2nd & 3rd trimesters
- Hb <100g/l postpartum
This guideline covers the prevention and management of iron deficiency anaemia during pregnancy and puerperium. It aims to ensure
This guideline is for use by midwives, obstetricians, and other members of the multidisciplinary team in Maternity. It is also of relevance to Primary Care – GPs, community pharmacists, and practice nurses who may be involved in the wider health care of pregnant women.
Iron deficiency is the most common cause of anaemia in pregnancy. Maternal anaemia can result in maternal fatigue, an increased risk of postpartum haemorrhage, and an increased risk of postpartum depression. It is associated with an increased risk of stillbirth, preterm birth and neonatal low ferritin levels.
Oral iron supplements can effectively treat iron deficiency anaemia. Supplements also have a role in treating low iron states and preventing the development of iron deficiency anaemia.



Normal ranges in pregnancy are:
| Ferritin | >30µg/l |
| Mean Cell Volume (MCV) | 88-109fl |
| Transferrin | 2-4g/l |
|
Ferritin |
<30 |
<30 |
>30 |
>30 |
|
MCV |
Low |
Normal |
Normal/Low |
Normal |
|
Transferrin |
High/ Normal/ Low |
High /Normal/ Low |
High |
Normal/ Low |
|
Cause |
Iron deficiency anaemia |
Iron deficiency anaemia |
Iron deficiency anaemia is likely |
Anaemia NOT likely to be due to iron deficiency. Look for other causes. |
A raised ferritin result can be a transient inflammatory marker. If a serum ferritin result is >270 µg/l, repeat bloods and consultant review are indicated. If oral iron has previously been prescribed, treatment should be paused until further blood results are reviewed, and an individualised plan agreed.
Anaemias that present with a low haemoglobin but a normal or high ferritin (>30µg/l) need careful review. There are other causes of anaemia and iron therapy may not be the appropriate treatment.
Consider other causes of anaemia e.g. folate or Vitamin B12 deficiency and check levels. If there is a strong clinical suspicion of iron deficiency anaemia, consider checking transferrin (request “iron studies” on Trakcare).
These conditions
can be associated with iron overload and therefore iron replacement is relatively contraindicated. Patients are likely to know they have these conditions.
Always consider the Hb result in conjunction with the serum ferritin result to confirm iron deficiency and exclude iron overload.
Discussion with a haematologist should take place before giving iron to women with these conditions.
A. First Line: Oral Iron
The first line iron therapy for both prevention and treatment of anaemia is one tablet of oral iron once daily. Recent evidence shows once daily dosing is as effective as twice or three times a day but has fewer side effects, so compliance is increased. Alternate day dosing is possible for women unable to tolerate daily dosing.
Ferrous fumarate or ferrous sulphate are suitable oral iron preparations. Sodium feredetate 5-10ml daily is a liquid alternative.
Women should be offered advice on how to take iron
All women commenced on oral iron should continue on oral iron throughout the pregnancy, and for three months postpartum. For women commencing iron in the postnatal period oral iron should continue for at least three months.
Prescription requests to GPs should ideally be made through Clinical Portal. Local alternative arrangements may be in place in some areas. Women can be notified of results and prescription requests through the Badger App. Midwives can use the Midwifery Formulary to supply oral iron NMC | Practising as a Midwife in the UK.
B. Monitoring for a response to oral iron therapy
When oral iron is commenced as treatment for iron deficiency anaemia the effectiveness of the treatment should be monitored.
Discussion with the obstetric team for individualised management is essential when
C. Second Line: Intravenous Iron
Intravenous iron is an alternative to oral iron for the treatment of anaemia. Careful consideration should be given to the use of intravenous iron as a range of common to rare side effects can be experienced.
It is intended for the treatment of significant iron deficiency anaemia – low haemoglobin and low ferritin in consultation with the obstetric team.
Indications for intravenous iron include
| Benefits: | Intravenous iron can improve iron stores and haemoglobin. Its use should be limited, as oral iron taken reliably is equally effective. |
| Risks: | Rarely hypersensitivity and anaphylactoid reactions can occur -between 1 in 1000 and 1 in 10,000 people may be affected [BNF). Extravasation can occur and cause permanent brown discoloration to the skin. |
| Alternatives: | Iron rich diet, oral iron, blood transfusion. |
| Nothing: | If untreated iron deficiency anaemia will not resolve. |
If a woman is not taking oral iron as recommended, or reports poor tolerance of oral iron, intravenous iron is not indicated. The second line in this circumstance should instead be to discuss and offer (see section 10a)
It is essential that ferritin levels are checked prior to intravenous iron.
Contraindications for intravenous iron
Refer to the GGC guideline for Iron Deficiency Anaemia (IDA) in Adults: Oral and Intravenous Iron Therapy Treatment available on Right Decisions platform - Iron Deficiency Anaemia (IDA) in Adults: Oral and Intravenous Iron Therapy Treatment (662) | Right Decisions
Ferinject (ferric carboxymaltose) should be used in obstetrics - prescribing-and-administration-information-for-ferinject.pdf
Please note it is recommended that oral iron is stopped 48h prior to administration of intravenous iron and should be withheld for five days after, if ongoing oral treatment is required.
All women commenced on oral iron during pregnancy should continue on oral iron for three months postpartum.
The immediate postnatal management of anaemia will be determined by haemoglobin levels and a woman’s clinical condition. Refer to GGC Guideline Blood Transfusion in Stable Postpartum Patients
Postnatal

Intravenous iron can be used in a stable postpartum woman who is not actively bleeding or requiring immediate increase in Hb. An increase in haemoglobin of 30g/l can be expected in 14 days.